Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab

The IL-17A inhibitor secukinumab is efficacious for the treatment of psoriasis. To better understand its mechanism of action, we investigated its impact on psoriatic lesions from 15 patients with moderate-to-severe plaque psoriasis undergoing secukinumab treatment. We characterized the longitudinal...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jared, Chang, Hsin-Wen, Grewal, Robby, Cummins, Daniel D., Bui, Audrey, Beck, Kristen M., Sekhon, Sahil, Yan, Di, Huang, Zhi-Ming, Schmidt, Timothy H., Yang, Eric J., Sanchez, Isabelle M., Nakamura, Mio, Bhattarai, Shrishti, Thibodeaux, Quinn, Ahn, Richard, Pauli, Mariela, Bhutani, Tina, Rosenblum, Michael D., Liao, Wilson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214344/
https://www.ncbi.nlm.nih.gov/pubmed/35757784
http://dx.doi.org/10.1016/j.xjidi.2021.100094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214344/
https://www.ncbi.nlm.nih.gov/pubmed/35757784
http://dx.doi.org/10.1016/j.xjidi.2021.100094

Ejemplares similares